The decreased expression of PCK2 may promote EMT by activating cytokines, a series of signaling pathways and altering immune infiltration, and ultimately lead to tumor immune evasion, low survival rate and increased invasivity in patients with liver cancer. The gene discussed is PCK2; the disease is neoplasm.